Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03593772 · ClinicalTrials.gov registry record · NA

Mission Reconnect-Veterans and Their Partners to Manage Pain and PTSD (MR)

A NA study of PTSD and Chronic Musculoskeletal Pain, sponsored by VA Office of Research and Development.

Completed
Registry status
NA
Development phase
730
Enrollment target
3
Study locations

NCT03593772: Completed NA study of PTSD and Chronic Musculoskeletal Pain, sponsored by VA Office of Research and Development.

NCT03593772 is a NA study of PTSD and Chronic Musculoskeletal Pain that has completed, run by VA Office of Research and Development. The registered enrollment target is 730 participants, above the 297-participant average among 154 other PTSD trials with a reported enrollment target (146% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03593772, a NA study of PTSD and Chronic Musculoskeletal Pain, has completed, sponsored by VA Office of Research and Development.

COMPLETED
Registry status
NA
Development phase
730 participants
Enrollment target
3
Study locations

Study Summary

This project is responsive to Rehabilitation Research and Development's (RR\&D) current special areas of interest for non-pharmacological activity-based interventions for chronic pain impacting pain reduction, function and quality of life. This project aligns with the VA mandate for complementary and integrative health (CIH) care for Veterans and their families. CIH complements traditional care for Veterans managing chronic conditions, such as chronic pain and PTSD. Mission Reconnect (MR) is a user-driven, dyadic, CIH self-care management program delivered remotely that teaches techniques the Veteran/partner dyad can use to reduce pain, anxiety and stress, promote well-being and improve relationship quality. The research goal is to evaluate MR as an approach to manage chronic pain and PTSD symptoms, for potential subsequent implementation. This study will possibly provide a model for establishing remote access and sustainable implementation of CIH within VA.

Primary Outcome

20-item questionnaire, used to assess pain, and pain-related subdomains, such as pain intensity, interference with activities, mobility, negative affect, vitality, and pain-related fear. Higher Scores associated with more adverse pain-related patient reported outcomes. Pain Range: 0 - 10 Mobility Range: 0 - 40 Activities of Daily Living Range: 0 - 40 Vitality Range: 0 - 30 Negative Affect Range: 0 - 50 Fear Range: 0 - 20 Total Range: 0-190

Interventions

  • BEHAVIORAL Mission Reconnect

Study Locations (3)

Florida

  • James A. Haley Veterans' Hospital, Tampa, FL - Tampa

Michigan

  • VA Ann Arbor Healthcare System, Ann Arbor, MI - Ann Arbor

Washington

  • VA Puget Sound Health Care System Seattle Division, Seattle, WA - Seattle

Trial Details

FieldValue
Enrollment Target 730 participants
Start Date 2019-10-08
Est. Completion 2022-10-31
Phase NA
VA Office of Research and Development

1,668 total trials

What the finished NCT03593772 record still lists

NCT03593772 is an interventional study that assigns participants to a tested intervention. The registered 730 participants enrollment target is mid-sized for trials with a published cap, above the 297-participant average among 154 other PTSD trials with a reported enrollment target (146% higher).

The record links to 2 conditions, with PTSD appearing as the primary indexed condition, and to 1 intervention - of which Mission Reconnect is the first listed.

NCT03593772 reports a single indexed study location in Florida, Michigan, Washington.

Frequently Asked Questions

What is clinical trial NCT03593772 about?

NCT03593772 is a clinical study titled "Mission Reconnect-Veterans and Their Partners to Manage Pain and PTSD (MR)". This project is responsive to Rehabilitation Research and Development's (RR\&D) current special areas of interest for non-pharmacological activity-based interventions for chronic pain impacting pain reduction, function and quality of life. This project aligns with the VA mandate for complementary an...

What is the current status of trial NCT03593772?

This trial is currently completed. It is a NA study. The enrollment target is 730 participants. The study started on 2019-10-08. Estimated completion is 2022-10-31.

What conditions does trial NCT03593772 study?

This clinical trial studies the following conditions: PTSD, Chronic Musculoskeletal Pain.

What interventions are being tested in trial NCT03593772?

The interventions under investigation include: Mission Reconnect (BEHAVIORAL).

Who is sponsoring clinical trial NCT03593772?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03593772 being conducted?

This trial has 3 study locations across Florida, Michigan, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for PTSD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03593772's enrollment target sits among peer trials

730 7th of 154 higher than 148 of 154 other PTSD trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other PTSD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03232918 · 730 participants · Phase 4

    Oxytocin and Fetal Heart Rate Changes

  • NCT05548283 · 730 participants · Phase 4

    Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

  • NCT07312162 · 730 participants

    Multilevel Determinants of Socioeconomic Disparities in Geographic Late-Stage Hepatocellular Carcinoma Hotspots

  • NCT05065216 · 728 participants · Phase 2

    Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03593772, the US trial registry maintained by the National Library of Medicine. NCT03593772 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.